IL176333A0 - Tellurium derivatives for prevention and treatment of neurodegenerative processes - Google Patents

Tellurium derivatives for prevention and treatment of neurodegenerative processes

Info

Publication number
IL176333A0
IL176333A0 IL176333A IL17633306A IL176333A0 IL 176333 A0 IL176333 A0 IL 176333A0 IL 176333 A IL176333 A IL 176333A IL 17633306 A IL17633306 A IL 17633306A IL 176333 A0 IL176333 A0 IL 176333A0
Authority
IL
Israel
Prior art keywords
prevention
treatment
neurodegenerative processes
tellurium
derivatives
Prior art date
Application number
IL176333A
Other languages
English (en)
Original Assignee
Michael Albeck
Biomas Ltd
Benjamin Sredni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Albeck, Biomas Ltd, Benjamin Sredni filed Critical Michael Albeck
Publication of IL176333A0 publication Critical patent/IL176333A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL176333A 2003-12-18 2006-06-15 Tellurium derivatives for prevention and treatment of neurodegenerative processes IL176333A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53049003P 2003-12-18 2003-12-18
PCT/IB2004/004163 WO2005060341A2 (en) 2003-12-18 2004-12-15 Tellurium derivatives for prevention and treatment of neurodegenerative processes

Publications (1)

Publication Number Publication Date
IL176333A0 true IL176333A0 (en) 2006-10-05

Family

ID=34710166

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176333A IL176333A0 (en) 2003-12-18 2006-06-15 Tellurium derivatives for prevention and treatment of neurodegenerative processes

Country Status (7)

Country Link
US (2) US7629382B2 (enExample)
EP (1) EP1694313A4 (enExample)
JP (1) JP2007514732A (enExample)
AU (1) AU2004304716B2 (enExample)
CA (1) CA2550459C (enExample)
IL (1) IL176333A0 (enExample)
WO (1) WO2005060341A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694313A4 (en) 2003-12-18 2010-11-17 Biomas Ltd TELLURIUM DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE PROCESSES
EP1796660B1 (en) 2004-09-17 2016-11-23 BioMAS Ltd. Use of ammonium trichloro(dioxyethylene-o,o')tellurate (as101) for the inhibition of interleukin-1beta-converting enzyme
US20080260770A1 (en) * 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants
US9216197B2 (en) 2006-09-11 2015-12-22 Biomas Ltd. Topical formulations of tellurium-containing compounds
CA2705944C (en) * 2007-11-23 2017-10-24 Biomas Ltd. Methods and compositions for inhibiting integrins using tellurium-containing compounds
US20100321208A1 (en) * 2009-06-23 2010-12-23 Craig Stephen Etchegoyen System and Method for Emergency Communications

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369550A (en) * 1967-02-17 1968-02-20 Thomas A. Armao Cryogenic clamps
GB1427415A (en) 1973-09-21 1976-03-10 Armao T A Cryosurgical instruments
US4962207A (en) * 1985-09-30 1990-10-09 Bar-Ilan University Organic derivatives of tellurium and selenium
US5102908A (en) * 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
US4761490A (en) * 1985-03-15 1988-08-02 Bar-Ilan University Organic derivatives of tellurium and selenium and their use to stimulate cytokine production
US5093135A (en) * 1985-09-30 1992-03-03 Michael Albeck Compounds for the induction of in vivo and in vitro production of cytokines
US4752614A (en) * 1985-09-30 1988-06-21 Bar-Ilan University Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4929739A (en) * 1988-03-24 1990-05-29 Bar-Ilan University Complexes of tellurium and selenium derivatives
DE4007473A1 (de) 1990-03-09 1991-09-12 Tomsk G Med I Kryoskalpell
US5271925A (en) * 1990-03-09 1993-12-21 Benjamin Sredni Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound
SE9200502D0 (sv) * 1992-02-20 1992-02-20 Astra Ab Novel antioxidants
US5262149A (en) * 1992-08-13 1993-11-16 Benjamin Sredni Method of treating or preventing alopecia
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
WO1996006618A1 (en) * 1994-09-01 1996-03-07 Pharmacia & Upjohn Company Cosolvent parenteral formulation of tirilazad
US5576347A (en) * 1994-11-14 1996-11-19 Sredni; Benjamin Method of treating gastric ulcers
US5654328A (en) * 1994-12-15 1997-08-05 Sredni; Benjamin Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
WO1996018401A1 (en) 1994-12-15 1996-06-20 Baker Norton Pharmaceuticals, Inc. Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound
US6428534B1 (en) * 1999-02-24 2002-08-06 Cryovascular Systems, Inc. Cryogenic angioplasty catheter
CA2369095C (en) * 1999-04-08 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
WO2001098325A1 (en) 2000-06-19 2001-12-27 University Of Southern California Methods for treating and preventing alopecia
US6747008B1 (en) * 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
US20030148970A1 (en) * 2001-01-12 2003-08-07 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-4
US6472381B1 (en) * 2001-10-12 2002-10-29 Biomas Inc. Method of treating psoriasis
IL146694A (en) * 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
AU2004246895A1 (en) * 2003-06-12 2004-12-23 Biomas Ltd. Methods of treating obesity and related disorders using tellurium and selenium compounds
EP1694313A4 (en) 2003-12-18 2010-11-17 Biomas Ltd TELLURIUM DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE PROCESSES
EP1796660B1 (en) 2004-09-17 2016-11-23 BioMAS Ltd. Use of ammonium trichloro(dioxyethylene-o,o')tellurate (as101) for the inhibition of interleukin-1beta-converting enzyme
US20080260770A1 (en) * 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants

Also Published As

Publication number Publication date
CA2550459A1 (en) 2005-07-07
WO2005060341A3 (en) 2006-09-28
US20100062081A1 (en) 2010-03-11
AU2004304716A1 (en) 2005-07-07
WO2005060341A2 (en) 2005-07-07
US20060063750A1 (en) 2006-03-23
CA2550459C (en) 2009-12-15
JP2007514732A (ja) 2007-06-07
AU2004304716B2 (en) 2010-05-27
US7629382B2 (en) 2009-12-08
EP1694313A2 (en) 2006-08-30
EP1694313A4 (en) 2010-11-17

Similar Documents

Publication Publication Date Title
GB2415378B (en) Treatment of neurodegenerative conditions
GB2422373B (en) Treatment of neurodegenerative conditions
AU2003219934A1 (en) Method of treatment or prevention of obesity
EP1628530B8 (en) Methods and compositions for the prevention and treatment of sepsis
AP2005003274A0 (en) Thiazole compounds for the treatment of neurodegenerative disorders
IL174767A0 (en) Inhibition of fgrf3 and treatment of multiple myeloma
EP1654260A4 (en) 6-LOW HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
GB2418025B (en) Device for the prevention or treatment of ulcers
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
IL175535A0 (en) Compositions for treatment of neurodegenerative diseases
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
AU2003904328A0 (en) Diagnosis and treatment of neurodegenerative disorders
IL176333A0 (en) Tellurium derivatives for prevention and treatment of neurodegenerative processes
GB0300783D0 (en) Treatment of neurodegenerative conditions
GB0302572D0 (en) Method of treatment
AU2003259833A8 (en) Methods of treating neurodegenerative diseases
PL1812797T3 (pl) Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom
EP1671648A4 (en) PREVENTION AND TREATMENT OF GVHD
AU2003291730A8 (en) Methods and compositions for treating neurodegenerative diseases
EP1667672A4 (en) METHOD FOR PREVENTING AND / OR TREATING NEURODEEGENERATIVE ILLNESSES
EP1560592A4 (en) TREATMENT OF ALLGIELES
IL166083A0 (en) Methods for treatment and prevention of gastrointestinal conditions
GB2442164B (en) Treatment of neurodegenerative conditions
GB0319358D0 (en) Treatment of neurodegenerative conditions
GB0724618D0 (en) Treatment of neurodegenerative conditions

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees